« Back to Where We Work

United States

In the United States, ICAP works to strengthen the health of underserved communities by focusing on research and services for preventing HIV, reducing health disparities, and translating research findings into innovative programs. We work with local community based organizations, community boards, political groups, religious leaders, and community advocates to engage vulnerable populations in HIV testing, care, and treatment.

Current Projects

Our current portfolio focuses on development of new research studies, recruitment, and retention of research participants, intervention delivery, data collection, results reporting, and publication development and dissemination. ICAP administers clinical research studies under the HIV Prevention Trials Network and the Microbicides Trials Network. Our clinical research sites—the Harlem Prevention Center and the Bronx Prevention Center—enable access to populations for study participation and provide experienced staff and research facilities for HPTN and MTN studies and additional research activities.

Bronx Prevention Center

MTN-014: Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel

This study is examining the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (Funded by NIH)

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

This study is investigating the experimental microbicide gel tenofovir to protect women against HIV. The study will answer important questions about how much vaginal tenofovir gel, when used in combination with common vaginal products, will interfere with the local and or systemic exposure of the tenofovir, and vice versa, to optimize effectiveness as an HIV prevention tool. (Funded by CONRAD)

HPTN 076

HPTN 076 is a two-year study that will recruit over 130 sexually active women age 18 to 45 and evaluate the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for use in healthy, HIV-uninfected women.

Harlem Prevention Center

HPTN 067: ADAPT

The ADAPT Study (Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking) recruits men who have sex with men (MSM) and transgender women and is designed to identify oral pre-exposure prophylaxis (PrEP) pill-taking schedules that participants are more likely to follow and determine if these schedules influence healthier sexual practices. (Funded by NIH)

The STAR Study (Seek, Test and Retain)

STAR is a five-year study testing the effectiveness of respondent-driven sampling to seek and recruit substance-using Black men who have sex with men (MSM) at high risk for HIV. The study assesses the feasibility and cost-effectiveness of two linkage and retention strategies to develop innovative approaches to engage highest-risk, hard-to-reach individuals for HIV services and retain them in treatment. (Funded by NIH)

PrEP for Black MSM (Advancing PrEP)

This five-year, multi-method implementation study tests an enhanced PrEP adherence package against a standard package in a randomized clinical trial located in a community setting. The study compares the effectiveness of both approaches, assessing patterns and monitoring changes in risk behaviors among black men who have sex with men (MSM) and transwomen participants taking PrEP. (Funded by NIH)